One of the most salient topics in the United States right now in pharma is market access and drug affordability, and one thing that’s driving that topic in this moment are the drug pricing
Just days after the US presidential race officially narrowed to a contest between President Joe Biden and former president Donald Trump, it’s no surprise that Biden’s State of the Union spe
Generic drugs are incredibly important in the medical field, not only for their effectiveness, but also for their cost-saving potential for both manufacturers and customers.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh